Navigating the Frontier of Hematologic Malignancy Therapies (5 of 5 Modules)
This activity provides an overview of recent data supporting the potential utility of circulating tumor DNA to predict risk and inform personalized therapeutic decision making for patients with lymphoma.
Upon completion of this activity, participants should be better able to:
Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources